Similar articles

• A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.

  Infante JR, Cohen RB, Kim KB, Burris HA 3rd, Curt G, Emeribe U, Clemett D, Tomkinson HK, LoRusso PM. Infante JR, et al. Invest New Drugs. 2017 Oct;35(5):576-588. doi: 10.1007/s10637-017-0459-7. Epub 2017 Apr 19. Invest New Drugs. 2017. PMID: 28424891 Free PMC article. Clinical Trial.
• A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.

  LoRusso PM, Infante JR, Kim KB, Burris HA 3rd, Curt G, Emeribe U, Clemett D, Tomkinson HK, Cohen RB. LoRusso PM, et al. BMC Cancer. 2017 Mar 6;17(1):173. doi: 10.1186/s12885-017-3143-6. BMC Cancer. 2017. PMID: 28264648 Free PMC article. Clinical Trial.
• A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors.

  Fujisaka Y, Yamada Y, Yamamoto N, Horiike A, Tamura T. Fujisaka Y, et al. Jpn J Clin Oncol. 2010 Aug;40(8):732-8. doi: 10.1093/jjco/hyq047. Epub 2010 Apr 29. Jpn J Clin Oncol. 2010. PMID: 20430774 Clinical Trial.
• A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors.

  Leong S, Moss RA, Bowles DW, Ware JA, Zhou J, Spoerke JM, Lackner MR, Shankar G, Schutzman JL, van der Noll R, Voest EE, Schellens JHM. Leong S, et al. Oncologist. 2017 Dec;22(12):1491-1499. doi: 10.1634/theoncologist.2017-0090. Epub 2017 Aug 10. Oncologist. 2017. PMID: 28798270 Free PMC article. Clinical Trial.
• Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations.

  Boni JP, Hug B, Leister C, Sonnichsen D. Boni JP, et al. Semin Oncol. 2009 Dec;36 Suppl 3:S18-25. doi: 10.1053/j.seminoncol.2009.10.009. Semin Oncol. 2009. PMID: 19963096 Review.